LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

J. van den Bent, Martin; Eoli, Marica; Manuel Sepúlveda-Sánchez, Juan; Smits, Marion; Walenkamp, Annemiek; Frenel, Jean‐Sébastien; A. Brandes, Alba; M. Clément, Paul; J. French, Pim; J. Dubbink, Hendrikus; M. Kros, Johan; Weller, Michael; Chinot, Olivier; De Vos, Filip; Whenham, Nicolas; Sanghera, Paul; Looman, Jim; Lee, Ho‐Jin; de Geus, Jan-Peter; Nuyens, Sarah; Spruyt, Maarten; Brilhante, Joana; Gorlia, Thierry; Golfinopoulos, Vassilis

doi:10.1093/neuonc/nox213

Public

LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

Shared by NobleBlocks on Nov 1, 2017 • 12:00 AM UTC

Authors:

Martin J. van den Bent

Marica Eoli

Juan Manuel Sepúlveda-Sánchez

Abstract

Depatux-m is a tumor-specific antibody-drug-conjugate consisting of antibody (ABT-806) bound to the toxin monomethylauristatin-F. We investigated depatux-m in EGFR-amplified recurrent glioblastoma (40–50% of glioblastoma). EORTC-1410-BTG (NCT02343406) is a randomized open label phase II study. Eligi...

Subject

Temozolomide

Lomustine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!